Samsung completes hat-trick of big biosimilar approvals

04:32 EDT 25 Aug 2017 | Pharmafile

Samsung Bioepis has announced that it, alongside its partner Biogen, has secured European Commission approval for its biosimilar version of Humira. The biosimilar, which will be named Imraldi, will aim to take a substantial chunk in the future of the $16 billion in sales that Humira is expected to reap this year.

The approval for its Humira biosimilar adds to its previous marketing approval for Renflexis, a biosimilar of J&J’s Remicade and BBenepali, a biosimilars of Amgen’s Enbrel.

read more

Original Article: Samsung completes hat-trick of big biosimilar approvals


More From BioPortfolio on "Samsung completes hat-trick of big biosimilar approvals"

Quick Search


Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...